Evidence map›Paper›PMID 39774950›Full record

ArticleAnnals of hematology2025

Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.

Grégoire Cullot, Valérie Lagarde, Jean-Michel Cayuela, Valérie Prouzet-Mauléon, Béatrice Turcq, Yosr Hicheri, Lydia Roy, Thorsten Braun, Marie-Joelle Mozziconacci, Anne-Sophie Alary and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Grégoire CullotUniv. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France. gregoire.cullot@biol.ethz.ch.
Valérie LagardeUniv. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France.
Jean-Michel CayuelaLaboratory of Hematology, Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, University Paris Diderot, Paris, France.
Valérie Prouzet-MauléonUniv. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France.
Béatrice TurcqUniv. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France.
Yosr HicheriDepartment of Hematology, Institut Paoli-Calmettes, Marseille, France.
Lydia RoyFi-LMC Group, Léon Bérard Center, Lyon, France.
Thorsten BraunDepartment of Hematology Hospital Avicenne, Assistance Publique-Hopitaux de Paris, Bobigny, France.
Marie-Joelle MozziconacciDepartment of Molecular Biology, Institut Paoli-Calmettes, Marseille, France.
Anne-Sophie Alary *Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
Stéphanie Dulucq *Univ. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France. stephanie.dulucq@chu-bordeaux.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia patients largely benefit from an expanding tyrosine kinase inhibitors (TKIs) toolbox that has improved the outcome of both diseases. However, TKI success is continuously challenged by mutation-driven acquired resistance and therefore, close monitoring of clonal genetic diversity is necessary to ensure proper clinical management and adequate response to treatment. Here, we report the case of a ponatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) patient harboring a BCR::ABL1 p.I293_K294insSLLRD mutation. Using in vitro proliferation assays on newly generated Ba/F3 cell lines, we confirmed that the mutation confers moderate resistance to ponatinib, and to imatinib and nilotinib. In contrast, BCR::ABL1

Indexed as

Drug Resistance, NeoplasmFusion Proteins, bcr-ablMutationPrecursor Cell Lymphoblastic Leukemia-LymphomaCell Line, TumorHumansImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNiacinamideProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrazolesPyridazinesABL1 protein, humanasciminibBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablImidazolesNiacinamideponatinibProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrazolesPyridazinesALLBCR::ABL1Cancer resistanceCMLInsertion mutationTyrosine kinase inhibitor

Identifiers

PMID39774950
PMCPMC11971149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.